Physician profile
Patrick Campbell
NPI 1982135091
$3,386.58
in general payments reported to CMS, 2019-2025
33 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $159 · 2022: $75.96 · 2023: $532 · 2024: $1,238 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.79 |
| Education | $125.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.25 | 2023-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $631.61 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.08 | 2023-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $238.73 | 2023-2025 | Eohilia, Entyvio, Gattex |
| Gilead Sciences, INC. | $175.30 | 2023-2025 | |
| Genzyme Corporation | $168.45 | 2024-2025 | |
| Boston Scientific Corporation | $127.54 | 2021 | |
| Phathom Pharmaceuticals, INC. | $94.44 | 2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $75.96 | 2022 | |
| Pfizer INC. | $74.52 | 2024-2025 | |
| Ardelyx, INC. | $69.19 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $67.00 | 2024-2025 | Resmetirom, Rezdiffra |
| Lilly USA, LLC | $64.87 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $64.73 | 2023-2025 | Rebyota |
| Aimmune Therapeutics, INC. | $59.25 | 2025 | Zenpep |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $53.14 | 2023 | Talicia |
| Celltrion USA INC. | $41.60 | 2023-2024 | Zymfentra, Yuflyma |
| Intercept Pharmaceuticals, INC. | $41.44 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $35.79 | 2023 | Dupixent |
| Vivus LLC | $32.73 | 2025 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $30.62 | 2023-2025 | Linzess |
| Amgen INC. | $29.20 | 2023 | Avsola |
| Daiichi Sankyo INC. | $28.46 | 2024 | Injectafer |
| Organon LLC | $28.01 | 2023 | Hadlima, Renflexis |
| Alnylam Pharmaceuticals INC. | $27.13 | 2025 | Givlaari |
| Mylan Institutional INC. | $19.76 | 2023 | Hulio |
| Celgene Corporation | $18.00 | 2024 | Zeposia |
| Braintree Laboratories, INC. | $17.51 | 2023 | Sutab, Suflave |
| Astrazeneca Pharmaceuticals LP | $17.06 | 2025 | |
| Medtronic, INC. | $16.36 | 2023 | Pillcam |
| Mallinckrodt Hospital Products INC. | $15.81 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $13.69 | 2024 | Dificid |
| Sandoz INC. | $13.35 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.